Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors

Leukemia. 2015 Nov;29(11):2263-6. doi: 10.1038/leu.2015.96. Epub 2015 Apr 14.

Authors

W Wang¹, J E Cortes², P Lin¹, J D Khoury¹, D Ai¹, Z Tang¹, G Tang¹, J L Jorgensen¹, L J Medeiros¹, S Hu¹

Affiliations

¹ Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

PMID: 25931274
DOI: 10.1038/leu.2015.96

No abstract available

Publication types

Letter

MeSH terms

Adolescent
Adult
Aged
Aged, 80 and over
Child
Chromosomes, Human, Pair 8
Female
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / mortality
Male
Middle Aged
Protein Kinase Inhibitors / therapeutic use*
Protein-Tyrosine Kinases / antagonists & inhibitors*
Trisomy*

Substances

Protein Kinase Inhibitors
Protein-Tyrosine Kinases

Supplementary concepts

Chromosome 8, trisomy